Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2021 / Cilt: 31 - Sayı: 2

Assessment of Factors Affecting the Treatment Efficacyof Radioactive Iodine (I-131) Therapy in Patients withHyperthyroidism

Hipertiroidi Hastalarında Radyoaktif İyot (I-131) Tedavi Başarısını Etkileyen Faktörlerin Değerlendirilmesi

Pages
236–245
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was determined that 1 mm increase in nodule size decreased the treatment efficacy by 1.07 times (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Hyperthyroidism is an increase in hormone production in the thyroid gland and the exposure of tissues to the hormones of the thyroid glands in the circulation.
📊
Key Findings & Data:Methods: In this retrospective study, relevant clinical and laboratory data were recorded in database of Kayseri Training and Research Hospital, Endocrinology and Metabolism Diseases Outpatient Unit between 2013-2016.
💡
Conclusion & Impact:It was determined that 1 mm increase in nodule size decreased the treatment efficacy by 1.07 times (p
🔬Design:Research Article
📍Scope:2013-2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Hyperthyroidism is an increase in hormone production in the thyroid gland and the exposure of tissues to the hormones of the thyroid glands in the circulation. The most common causes encountered are Graves’ Disease, Toxic Multinodular Goiter and Toxic Adenoma. The purpose of radioactive iodine treatment is to make patients become euthyroid or hypothyroid. Despite adequate treatment, hyperthyroidism persists or reccurs in some patients. The aim of our study is to investigate the factors affecting the efficacy of radioactive iodine treatment in hyperthyroidism. Methods: In this retrospective study, relevant clinical and laboratory data were recorded in database of Kayseri Training and Research Hospital, Endocrinology and Metabolism Diseases Outpatient Unit between 2013-2016. Results: A total of 79 cases including 17 (21%) male, and 62 (79%) female patients were enrolled in the study. There were 33 (42%) Graves’ disease 9 (11%) Toxic Multinodular Goitre and 37 (47%) Toxic Adenoma patients when grouped according to diagnoses. Mean age was 56.5 ± 16,80. Development of hypothyroidism or euthyroidism were accepted as efficient treatment, hyperthyroidism or recurrence were considered as treatment failure. In 71 (89%) patients, treatment efficiently resulted in hypothyroidism or euthyroidism, whereas in 8 (11%) patients, the treatment failed due to recurrence or persistent disease. Treatment was 100 % effective in Toxic Multinodular Goitre and Toxic Adenoma groups, while it was effective in 75.7 of patients with Graves’ Disease. Patients who did not use antithyroid drugs recovered faster than patients who did. Conclusion: Radioactive iodine therapy is an efficient treatment in patients with hyperthyroidism. It was determined that 1 mm increase in nodule size decreased the treatment efficacy by 1.07 times (p

Özet

Amaç: Hipertiroidi, tiroid bezinde hormon üretiminde bir artış ve dokuların dolaşımdaki tiroid bezlerinin hormonla rına maruz kalmasıdır. En sık karşılaşılan nedenler Graves Hastalığı, Toksik Multinodüler Guatr ve Toksik Adenomdur.Radyoaktif iyot tedavisinin amacı hastaları ötiroid veya hipotiroidi haline getirmektir. Yeterli tedaviye rağmen,hipertiroidi bazı hastalarda devam eder veya tekrar eder. Çalışmamızın amacı hipertiroidide radyoaktif iyot tedavi sinin etkinliğini etkileyen faktörleri araştırmaktır. Yöntem: Bu retrospektif çalışmada, 2013-2016 yılları arasında Kayseri Eğitim ve Araştırma Hastanesi Endokrinolojive Metabolizma Hastalıkları Polikliniğinde klinik ve laboratuvar verileri kaydedildi. Bulgular: Çalışmaya toplam 79 hasta dahil edildi. Tanılara göre gruplandırıldığında 33 (% 42) Graves, 9 (% 11)Toksik Multinodüler Guatr ve 37 (% 47) Toksik Adenom hastası vardı. Yaş ortalaması 56,5 ± 16,80 idi. 17 hasta (%21) erkek, 62 hasta (% 79) kadındı. Hipotiroidizm veya ötiroidi gelişimi etkin tedavi olarak kabul edildi, hipertiroi dizm veya rekürrens tedavi başarısızlığı olarak kabul edildi. 71 hastada (% 89) tedavi etkin şekilde hipotiroidizmveya ötiroidizm ile sonuçlandı, 8 hastada (% 11) ise nüks veya kalıcı hastalık nedeniyle tedavi başarısız oldu. ToksikMultinodular Guatr ve Toksik Adenomda etkinlik oranı% 100 iken Graves hastalarında etkinlik oranı 75.7 idi.Antitroid ilaç kullanmayan hastalar, antitroid ilaç kullanan hastalardan daha hızlı iyileşti. Nodül boyutundaki 1mm’lik artışın tedavi etkinliğini 1,07 kat azalttığı tespit edildi (p

🔖

Cite This Article

ARIK, B. E., ARIK, F., GÖKAY, F. (2022). Assessment of Factors Affecting the Treatment Efficacyof Radioactive Iodine (I-131) Therapy in Patients withHyperthyroidism. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 31 - Sayı: 2, 236–245. https://ajindex.com/articles/558058

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Akarsu E AF, Altay M et.al. Tirotoksikoz ve Hipertiroidi. Türkiye Endokrinoloji ve Metabolizma Derneği, tiroid hastalıkları tanı ve tedavi klavuzu. 2019:54-67
  2. Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009;94(6):1853-78. [CrossRef] 3. Flynn RW, MacDonald TM, Morris AD, Jung RT, Leese GP. The thyroid epidemiology, audit, and research study: thyroid dysfunction in the general population. J Clin Endocrinol Metab. 2004;89(8):3879-84. [CrossRef] 4. Bahn Chair RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646. [CrossRef] 5. Howarth D, Epstein M, Lan L, Tan P, Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves’ disease: a clinical outcome study. Eur J Nucl Med. 2001;28(10):1489-95. [CrossRef] 6. Sgouros G, Kolbert KS, Sheikh A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45(8):1366-72
  3. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549-58. [CrossRef] 8. Gutekunst R, Becker W, Hehrmann R, Olbricht T, Pfannenstiel P. [Ultrasonic diagnosis of the thyroid gland]. Dtsch Med Wochenschr. 1988;113(27):1109-12. [CrossRef] 9. Maisey MN, Natarajan TK, Hurley PJ, Wagner HN, Jr. Validation of a rapid computerized method of measuring 99mTc pertechnetate uptake for routine assessment of thyroid structure and function. J Clin Endocrinol Metab. 1973;36(2):317-22. [CrossRef] 10. Schneider PB. Simple, rapid thyroid function testing with 99mTc-pertechnetate thyroid uptake ratio and neck/thigh ratio. AJR Am J Roentgenol. 1979;132(2):249-53. [CrossRef] 11. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2002;87(3):1073-7. [CrossRef] 12. Knapska-Kucharska M, Oszukowska L, Lewinski A. Analysis of demographic and clinical factors affecting the outcome of radioiodine therapy in patients with hyperthyroidism. Arch Med Sci. 2010;6(4):611-6. [CrossRef] 13. Schiavo M, Bagnara MC, Camerieri L, et al. Clinical